熱點掃描 | 教育股拉昇，全通教育漲近20%
uSMART盈立智投4月6日消息，截止發稿，港股三大指數漲跌互現，恆生指數下跌1.79%，報22098.79點，成交額600.05億；國企指數下跌1.9%，報7623.36點，成交額219.35億；紅籌指數上漲0.14%，報4086.57點，成交額38.44億。
教育股拉昇，全通教育漲近20%，豆神教育、博瑞傳播、傳智教育、學大教育漲超10%，開元教育、中公教育漲超6%；
石油股普漲，中海油漲超3%，中石油漲1.4%；中石化漲近1%；
抗疫概念股多數回調，復星醫藥跌超3%，君實生物跌超2%，中國生物製藥跌1.54%；
有色金屬板塊多數走低，贛鋒鋰業跌超4%，紫金礦業、中國鋁業跌近3%，洛陽鉬業跌超2%；
港股餐飲股走低，賞之味跌近48%，九毛九跌近5%，奈雪的茶跌超5%，百勝中國跌3.77%；
熱門股
香港航天科技盤中漲5.39%，報14.86港元，香港航天科技4月4日發佈公告，有關公司與山東產業技術研究院共同建構和運營首個高分辨率農業衛星星座的戰略合作。“金紫荊—齊魯衛星星座”第一期將由9顆衛星組成，其建造和發射將於今年完成；
綠景中國地產漲超35%，報1.43港元，該公司3月30日表示，深圳白石洲地價一期約18億，預期在本月初可以取得土地證，確保四證齊備，這對整個項目的推進是非常有正面影響的。白石洲一期現在地下施工正全面展開，土方已經基本結束。當前疫情反覆，對白石洲項目應該是影響是輕微的，沒有大的影響。按目前的施工進度來排，白石洲項目明年銷售在即。項目一期建築面積超過90萬平方米，權益佔比爲80%，有將近33萬平方米屬於可售部分。從目前周邊項目批覆的限售價看，按單價13萬計，一期預計可售貨值超過400億元；
藥明巨諾續漲7.37%，報9.76港元，藥明巨諾4月3日公佈，國家藥監局藥品審評中心已授予倍諾達(瑞基奧侖賽注射液)用於治療套細胞淋巴瘤的突破性治療藥物認定。倍諾達是公司自主開發的一款靶向CD19的自體嵌合抗原受體T細胞免疫治療產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
